If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Pfizer (PFE) . This company, which is in the Zacks Large Cap Pharmaceuticals industry, shows potential for another earnings beat.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 39.88% ...

Ian Read, chairman and chief executive officer of Pfizer Inc., gestures as he speaks during a panel session at the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 17, 2017.Activist Starboard Value accused Pfizer of threatening litigation against the company's former CEO and CFO in order to get them to break ranks with the investor's nascent turnaround campaign at the pharmaceutical giant.Starboard managing member Jeff Smith said in a Thursday letter to Pfizer's board that the company or i ...

Both of these stocks should have plenty of room to run.Are there misconceptions about investing? You bet there are. One of the biggest, in my opinion, is that you need a lot of money to get started. That's not true at all.You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare sector, it's an especially easy task. Here are two no-brainer healthcare stocks to buy with $200 right now.Pfizer: A better story than meets the eyeI can imagine som ...

Ian Read, chairman and chief executive officer of Pfizer, speaks as President Donald Trump, left, listens during an announcement on a new pharmaceutical glass packaging initiative in the Roosevelt Room of the White House in Washington, D.C., July 20, 2017.Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said Wednesday evening that they would step away from Starboard Value's campaign at the struggling pharmaceutical giant, just days after news of the activist's stake broke.Read and D'Amelio said they wer ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Guggenheim Securities, LLC is issuing a statement on behalf of former Pfizer CEO Ian Read and former Pfizer CFO Frank D’Amelio: We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value. ...

The sharp, sudden entry of an activist investor is raising hopes that change might come to the company.Pfizer (PFE 3.46%) was a stock on the move Wednesday, and not because of any news generated by the healthcare company. Reports of a meeting between Pfizer's leader and an activist investor breathed life into the stock, which closed the day more than 3% higher in price. That gain well exceeded the 0.7% increase of the S&P 500 index.An activist meeting is apparently imminentLate afternoon on Tuesday, the Fin ...

Pfizer (PFE, Financial) experienced a 2.3% increase, reaching $29.85. The rise follows news that Pfizer's CEO plans to meet next week with key leaders from activist investor Starboard Value. Starboard Value currently holds approximately $1 billion in Pfizer stock and is advocating for changes to improve the company's performance.In addition, Pfizer and its German partner BioNTech secured a legal victory in the London High Court, invalidating two patents held by competitor CureVac. The disputed technology un ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.The story of activist fund Starboard Value taking a $1 billion position ...

Ken Griffin's Citadel continues to add to its position in Pfizer.Each quarter, hedge funds that manage over $100 million are required to file a Form 13F with the Securities and Exchange Commission (SEC). These filings break down which stocks investment firms bought and sold during the most recent quarter.Ken Griffin is a billionaire investor who serves as CEO of the hedge fund Citadel. Last quarter, Citadel bought 7.9 million shares of Pfizer (PFE 0.93%) -- increasing its stake in the pharmaceutical giant b ...

KEY TAKEAWAYSPfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion stake in the struggling drugmaker.Bourla and at least one other director will hold discussions with Starboard next week, the Financial Times reported, in a sign that the hedge fund’s demands are being taken seriously by the COVID-19 vaccine maker. Pfizer's shares have halved since their pandemic peak in 2021 as demand for its COVID-19 vaccines slumped. Pfizer (PFE) Chief Ex ...